Mulay James reported grant involving 9,354 derivative units of CG Oncology, Inc. at $0.00 for $0 on Jun 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
9,354Director Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
9,354Direct
Trade date
Jun 4, 2026Grant
Filed
Jun 5, 2026, 4:30 PM ET1-day reporting delay
Accession
0001193125-26-259691Code A · Transaction 99255
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CGON price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CGON · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +25%1w ago +13%1d ago +1.3%
Returns since7d +11%30d +31%90d180d1y

Footnotes in full

F1: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.